New Vaccines in Development: What to Expect Next

Vaccine science is in the middle of a surge unlike anything before the pandemic, with more than a dozen entirely new platforms and hundreds of candidates moving through clinical trials for diseases that have never had a vaccine. The mRNA technology that powered COVID-19 shots is being refined to work at lower doses, survive without freezers, and target cancers. Meanwhile, researchers are closing in on goals that seemed out of reach a decade ago: a single flu shot that could replace annual boosters, a viable HIV vaccine strategy, and needle-free patches you could apply at home. What follows is a tour of the developments most likely to reach you in the coming years, from the science behind them to the practical obstacles still in the way.

Self-Amplifying RNA and the Next Wave of mRNA Vaccines

The mRNA vaccines you know from COVID-19 deliver a genetic instruction set that your cells read once to produce a target protein. Self-amplifying RNA, or saRNA, takes that a step further: once inside a cell, the molecule copies itself, producing far more protein from a much smaller starting dose. In animal studies comparing the two approaches head-to-head for influenza, a dose roughly 64 times smaller of saRNA gave protection equivalent to conventional mRNA.¹ That dose advantage matters for manufacturing speed, cost per shot, and reducing side effects tied to the amount of material injected.²

Japan approved the first saRNA vaccine for COVID-19 in late 2024, making it the first authorized product using this platform. Several more candidates are in trials for influenza, rabies, and respiratory syncytial virus (RSV). The technology is still being refined: the self-amplifying machinery can trigger stronger innate immune reactions than standard mRNA, and finding the right balance between amplification and tolerability is an active area of work.³

Solving the Cold-Chain Problem

One of the biggest practical barriers to mRNA vaccines is that they fall apart at room temperature. The Pfizer COVID-19 vaccine originally required ultra-cold storage at around minus 70 degrees Celsius, making distribution in tropical and low-resource settings a logistical nightmare. Researchers are attacking this problem from multiple angles, including freeze-drying techniques, new lipid-nanoparticle designs, and chemical stabilizers that protect the fragile RNA strand from heat and oxidation.⁴

One of the most striking recent results comes from an AI-driven approach that screened thousands of formulation combinations to find solid-state mRNA vaccines that kept their full potency after sitting at body temperature for two months. In animal tests, those formulations performed just as well as freshly prepared vaccines and could even be delivered through microneedle patches applied to the skin.⁵ If those results hold up in humans, they could reshape how vaccines reach rural clinics and disaster zones, where reliable refrigeration is the exception rather than the rule.

Universal Flu and Pan-Coronavirus Vaccines

Every fall, public health agencies guess which influenza strains will circulate and build that season’s vaccine around those predictions. When they guess wrong, effectiveness drops sharply. A universal flu vaccine would target parts of the virus that barely change from year to year, eliminating the need for annual reformulation. The most advanced strategy focuses on the stalk of hemagglutinin, a mushroom-shaped protein that influenza uses to enter cells. The stalk is far more conserved across strains than the head, which mutates rapidly.

A chimeric hemagglutinin approach, which tricks the immune system into focusing on the stalk by swapping in unfamiliar head domains, proved safe and generated broad, long-lasting antibody responses in a phase I trial.⁶ Several other universal flu candidates using different conserved targets are also in clinical testing.⁷ None are close to replacing seasonal shots yet, but even a vaccine that cuts the frequency of updates from yearly to every few years would be a significant win.

A parallel effort targets betacoronaviruses, the family that includes SARS-CoV-2, SARS, MERS, and some common cold viruses. Rather than chasing each new variant, researchers have identified stretches of viral protein that remain nearly identical across multiple betacoronavirus subgenera. A recent study mapped conserved T-cell targets across the entire SARS-CoV-2 proteome and found that including proteins beyond the spike dramatically improved the breadth of cross-reactive immune responses.⁸ Separate work has shown that vaccine designs built around these conserved epitopes can protect animals against both the Delta and Omicron lineages of SARS-CoV-2.⁹ The hope is that a pan-betacoronavirus vaccine could offer a baseline of protection against future spillover events from bats or other animal reservoirs, not just tomorrow’s Omicron offshoot.

Personalized Cancer Vaccines

The same mRNA technology behind COVID-19 shots is being repurposed as a cancer treatment. The idea is to sequence a patient’s tumor, identify the unique mutations on its surface, and build a custom mRNA vaccine that teaches the immune system to hunt those specific cells. Clinical trials are now underway for melanoma, lung cancer, pancreatic cancer, breast cancer, and glioblastoma, among others.¹⁰

The results so far are encouraging but still early. Individualized neoantigen vaccines have produced response rates above 50 percent in certain patient groups, and more than 150 trials are testing mRNA cancer vaccines, often in combination with checkpoint inhibitor drugs that release the brakes on immune cells.¹¹ The combination with checkpoint inhibitors has been especially promising in melanoma, where phase III trials of one candidate (mRNA-4157/V940 paired with pembrolizumab) are underway.¹²

Cancer vaccines are fundamentally different from infectious-disease vaccines. You are not trying to prevent a future infection but to destroy a disease already present, in a patient whose immune system the tumor has been actively suppressing. Manufacturing timelines also matter: a personalized vaccine has to be designed, produced, and delivered while the patient is still well enough to benefit. Compressing that turnaround time from weeks to days is one of the main engineering challenges the field is working through.

Nasal Sprays, Skin Patches, and Other Needle-Free Routes

Most vaccines today are injected into muscle, which generates strong antibody responses in the bloodstream but relatively weak immunity at the body surfaces where respiratory viruses actually land. Intranasal vaccines aim to fix that mismatch by delivering antigens directly to the lining of the nose and airways, triggering the production of secretory IgA antibodies right at the point of entry. Those mucosal antibodies appear to offer broader cross-protection against viral variants than the IgG antibodies generated by standard injections.¹³

An interesting twist is that nasal boosters given after a conventional injected vaccine seem to work well even without adjuvants, which are the immune-stimulating additives normally needed to make a vaccine effective. Research in mice showed that an intranasal protein booster, given after an initial mRNA shot, redirected immune cells primed in lymph nodes into the lungs, where they quickly began producing IgA.¹⁴ Intranasal vaccines using different formulations have also produced secretory IgA with strong cross-variant neutralizing ability against multiple SARS-CoV-2 lineages.¹⁵ Several nasal COVID-19 and flu vaccines are already authorized in some countries, though the field is still working out how to make mucosal immunity as durable as the systemic kind.

Microneedle patches are another delivery method gaining ground. These are small adhesive patches studded with tiny, often dissolvable projections that penetrate just the outer layer of skin. The skin is packed with immune cells, so transdermal delivery can trigger strong immune activation while avoiding the need for trained health workers and sharps disposal.¹⁶ 3D-printed microneedle arrays coated with vaccine components have outperformed standard subcutaneous injection in activating immune cells in draining lymph nodes in animal studies.¹⁷ Combined with the thermostable mRNA formulations mentioned earlier, patches could eventually make self-administered, room-temperature vaccination a reality.

Vaccines for Diseases That Have Dodged Us

Some pathogens have resisted vaccine development for decades. HIV is the most famous example. The virus mutates so quickly and hides so effectively that conventional approaches have failed repeatedly. A newer strategy called germline targeting takes a step-by-step approach: the first immunization is designed not to produce final protective antibodies itself, but to activate the rare precursor B cells that could, with further coaxing, mature into cells capable of making broadly neutralizing antibodies. A first-in-human trial of one such immunogen (eOD-GT8) confirmed that it could find and activate the right precursor cells in people.¹⁸ Follow-up work with a related immunogen in primates showed that this priming step can lead to antibodies that neutralize real, hard-to-neutralize HIV strains.¹⁹ An effective HIV vaccine would likely require a sequence of different shots over time, each guiding B cells closer to producing broadly protective antibodies, a concept validated by the foundational work showing that the right precursor cells exist at usable frequencies in uninfected people.²⁰ It is a marathon, not a sprint, but these are the most concrete steps forward in decades.

Tuberculosis kills more people each year than any other single infectious agent, yet the only licensed vaccine, BCG, was developed over a century ago and provides inconsistent protection in adults. A newer candidate called M72/AS01E showed roughly 50 percent efficacy against active TB disease in a large trial across Kenya, South Africa, and Zambia, with protection lasting at least three years.²¹ That number may sound modest, but given the scale of TB globally, even a partially effective vaccine could prevent millions of cases.

Lyme disease is another gap that may soon be filled. An earlier Lyme vaccine was pulled from the U.S. market in 2002 after poor sales and controversy, but a new candidate called VLA15, now being co-developed by Pfizer and Valneva, targets six outer surface protein A serotypes covering the Borrelia species found in both North America and Europe. It proved safe and immunogenic in a phase I trial, generating antibody responses across all targeted serotypes.²² Phase III data should determine whether it reaches the market within the next few years.²³

Combination Shots and Fewer Appointments

If you could get a single injection that covered COVID-19 and RSV at once, you would cut your annual vaccine visits in half for respiratory illnesses. That is the logic behind combination mRNA vaccines now in development. In one preclinical study, a bivalent mRNA formulation encoding both the SARS-CoV-2 Omicron spike protein and the RSV fusion protein generated strong antibody and cellular immune responses against both viruses in mice, and protected animals from infection with either pathogen.²⁴ Moderna and Pfizer have both moved flu-plus-COVID combination candidates into clinical trials, and broader respiratory panels that also include RSV or human metapneumovirus are on the drawing board.²⁵

The challenge with combination vaccines is that different antigens can interfere with each other’s immune responses when mixed. Dose ratios, lipid nanoparticle composition, and the order in which the immune system encounters each antigen all have to be optimized. Still, the convenience factor is a powerful motivator: simpler schedules improve uptake, which is especially important for older adults who are at highest risk from respiratory infections.

Better Vaccines for Aging Immune Systems

Older adults are both the group most vulnerable to infections and the group least likely to mount a strong response to vaccination. The immune system gradually loses potency with age: T cells become less diverse, B cells produce fewer high-quality antibodies, and a baseline of chronic, low-grade inflammation accumulates.²⁶ Strategies for overcoming this include higher antigen doses (as in the high-dose flu vaccine already available), intradermal delivery that takes advantage of the skin’s rich immune cell population, and newer adjuvants that give the aging immune system a stronger kickstart.

Two adjuvant systems have already proven their value in older populations. The oil-in-water emulsions MF59 and AS03 are used in influenza vaccines and have been shown to boost immunogenicity in older recipients. The liposome-based adjuvant AS01, used in the shingles vaccine Shingrix, demonstrated very high efficacy against herpes zoster in older adults in clinical trials.²⁷ Next-generation adjuvant formulations are being designed specifically to counteract the blunted innate immune responses that come with aging, a recognition that a vaccine effective in a 30-year-old may not work the same way in a 75-year-old.

AI, Structural Biology, and How Vaccines Get Designed Now

Vaccine design used to be largely empirical: grow a pathogen, weaken or kill it, inject it, and see what happens. Modern structural biology and machine learning have transformed the process into something closer to precision engineering. Deep learning tools are now used in three main areas: predicting protein structures, analyzing the vast diversity of immune cell receptors in a population, and modeling how pathogens evolve to escape immunity.²⁸ These models help researchers identify which parts of a pathogen are most likely to trigger a useful immune response and which are evolutionary dead ends.

A concrete example involves hepatitis C, a virus that has eluded vaccine development partly because its surface proteins are unstable and hard to reproduce in their natural shape. Researchers recently engineered a native-like version of the HCV envelope protein complex and mounted it on self-assembling nanoparticles, creating a vaccine candidate that presents the viral surface to the immune system the way the real virus would.²⁹ Structure-guided design of this kind, increasingly aided by AI prediction tools, is becoming the default approach for difficult targets.

Manufacturing Without Factories

Even the best vaccine is useless if it cannot be produced at scale and delivered where it is needed. One emerging approach is cell-free manufacturing, in which the molecular machinery for making proteins is extracted from cells, freeze-dried, and shipped as a shelf-stable kit. When needed, the kit is rehydrated, fed a genetic template, and produces vaccine components on site. This kind of decentralized production has been demonstrated across multiple international sites with performance comparable to commercial standards.³⁰ A related platform has been shown to produce immunogenic conjugate vaccines in a two-step cell-free process, emphasizing rapid response to outbreaks.³¹

On the political and equity side, the WHO established an mRNA technology transfer program in 2021, centered on a hub in South Africa and 15 partner producers in middle-income countries. The goal is to build local manufacturing capacity so that the next pandemic does not repeat the stark disparities in vaccine access seen during COVID-19.³² The program has faced real tensions around intellectual property, technology readiness, and sustained funding, and progress has been slower than hoped.³³ Still, the infrastructure being built now will matter enormously for how quickly future vaccines reach low-income regions.

Immune Imprinting and Why Updating Vaccines Is Harder Than It Sounds

One challenge that looms over all next-generation vaccine strategies is immune imprinting, sometimes called “original antigenic sin.” When your immune system first encounters a virus or vaccine, it forms a strong memory of that version. When a new, updated vaccine arrives, the immune system tends to preferentially recall those original memory cells rather than building new ones tailored to the current threat. Research on the XBB.1.5 COVID-19 booster showed that while the updated shot did boost neutralizing antibodies against newer variants, the response was dominated by recall of memory B cells originally primed by the ancestral Wuhan strain, not by fresh responses to XBB.1.5 itself.³⁴

This imprinting effect also had a measurable impact on cross-variant coverage. The XBB.1.5 booster successfully raised antibody levels against the vaccine-matched strain and several related variants, but neutralizing titers against JN.1, the lineage from which currently dominant strains descend, were about four-fold lower than against XBB.1.5 regardless of prior vaccine history.³⁵ The practical takeaway is that simply swapping in a new spike sequence with each update may not fully redirect the immune response. Strategies to overcome imprinting, including longer intervals between doses, multivalent formulations, and vaccines that target non-spike proteins, are all being actively explored. For universal vaccine efforts aimed at flu and coronaviruses alike, solving the imprinting puzzle is not an afterthought but a central design constraint.